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Among 126 consecutive patients undergoing percutaneous mitral
valvuloplasty, 34 were judged to be at high risk for surgery on the
basis of age >70 years (n = 13), New York Heart Association
functional class IV (n =11), ejection fraction :::;35% (n =3),
severe pulmonary hypertension (n = 7), need for associated
coronary bypass (n =4) or additional valve surgery (n =20) or
severe pulmonary disease (n = 3). Baseline features of the high
risk group were substantially worse than those of the other
patients: age (65 ± 11 versus 49 ± 12 years; p =0.0001) and
echocardiographic score (9.4 ± 1.8 versus 8.2 ± 1.5; p =0.005)
were higher, whereas cardiac output (2.9 ± 0.9 versus 4.1 ± 1.2
liters/min; p =0.0001) and mitral valve area (0.9 ± 0.4 versus 1.1
± 0.3 mm2; p =0.002) were lower.
Three high risk patients experienced technical failures and
three others had major complications. Among the remaining 28
patients, 18 (65%) had a complete hemodynamic success, 4 (14%)
an incomplete success and 6(21 %) hemodynamic failure. Stepwise
To date, results (1-7) reported with percutaneous mitral
valvuloplasty have established this procedure as a rational
approach to the treatment of symptomatic mitral stenosis. It
is similar to closed surgical commissurotomy (8,9) in that
both procedures produce excellent results, with a low risk in
young patients with mobile, pliable, minimally thickened and
only mildly calcified valves. Results are less satisfactory in
elderly patients who more frequently exhibit immobile,
thickened and calcified valves and who are more likely to
undergo valve replacement. Percutaneous mitral valvulo-
plasty has been proposed as an alternative for patients at
high risk for surgery or for whom surgery is contraindicated
(10-12).
The purpose of this study was to assess the immediate
and long-term results of percutaneous mitral valvuloplasty in
patients with symptomatic mitral stenosis at high risk for
mitral valve surgery.
From the Department of Medicine, Montreal Heart Institute. Montreal,
Quebec, Canada. This study was presented in part at the 39th Annual Meeting
of the American College ofCardiology, New Orleans, Louisiana, March 1990.
Manuscript received April 2, 1990; revised manuscript received August
29, 1990, accepted September II. 1990.
Address for reprints: Raoul Bonan, MD, Montreal Heart Institute. 5000
East Belanger Street, Montreal, Quebec HIT IC8. Canada.
© 1991 by the American College of Cardiology
logistic regression analysis retained echocardiographic score as
the only factor independently predictive of success. The percent
increase in mitral valve area also correlated with echocardio-
graphic score (r =0.51, P < 0.01). Mitral regurgitation did not
change after the procedure in 15 (56%) of 27 patients and
increased by one grade in the remaining 12. Atrial shunting was
detected by venovenous dye-dilution curves in 71 %ofthe patients,
but only 4 (14%) had a pulmonary to systemic flow ratio>1.5.
Three patients (9%) died within 48 h of the procedure and by 6
months, three additional patients had died. Twenty (80%) of
survivors had improvement by at least one functional class.
Thus, in patients at high surgical risk, the risk of percutaneous
mitral valvuloplasty is also increased, but is acceptable compared
with that of surgery. Although high risk patients have more severe
mitral stenosis and less hemodynamic improvement, their clinical
status 6 months after valvuloplasty usually is greatly improved.
(J Am Coil CardioI1991;17:348-54)
Methods
Study patients (Table 1). Among 126 consecutive cases of
percutaneous mitral valvuloplasty performed from March
1987 to July 1989 at the Montreal Heart Institute, we
retrospectively identified 34 patients at high surgical risk,
defined as age >70 years (n = 13), New York Heart
Association class IV (n = II), ejection fraction ~35% (n =
3), severe pulmonary hypertension before valvuloplasty with
pulmonary arteriolar resistance >800 dynes·s- l ·cm- 5
(n = 7), need for associated coronary surgery (n = 4) or
additional valve surgery (n = 20) or severe pulmonary
disease with a forced expiratory volume ~1,000 mils (n = 3).
Associated valve diseases were tricuspid stenosis in 3 pa-
tients, tricuspid regurgitation in II, mild aortic regurgitation
in 4 and aortic stenosis in 4. On the basis of previous studies
(13-16), the operative mortality rate in these high risk
patients was expected to be > 15%, compared with that in
the remaining 92 low risk patients who were excellent
surgical candidates with an expected mortality rate in the
range of 1% to 3%.
Echocardiographic measurements (Table 2). M-mode and
two-dimensional echocardiographic studies were obtained
the day before, between 24 and 48 h after and 6 months after
the procedure. Left atrial diameter was measured from the
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Table 1. Clinical Characteristics of 34 High Risk and 92 Low Risk
Study Patients
High Risk Low Risk p
(n = 34) (n = 92) Value
Age (yr) 65 ± 11 49 ± 12 0.0001
Gender (F/M) 29/5 83/9 NS
Previous embolism 18% 13% NS
Prior mitral commissurotomy 18% 24% NS
Atrial fibrillation 53% 30% 0.02
Oral anticoagulants 59% 40% 0.03
Mitral calcification 68% 44% 0.03
(fluoroscopy)
NYHA class III or IV 88% 57% 0.0001
F = feminine; M = masculine; NYHA = New York Heart Association.
M-mode echocardiogram as previously described (17). Mor-
phologic characteristics of the mitral apparatus before val-
vuloplasty were evaluated according to the scoring system of
Wilkins et al. (18). Baseline echocardiographic features of
the mitral valve are listed in Table 2.
Procedure and hemodynamic measurements. Informed
consent for the procedure was obtained from all patients.
The consent form was approved by the Ethics Committee of
our hospital. Before percutaneous mitral valvuloplasty, right
and left heart pressures, oximetry and arteriovenous and
venovenous dye-dilution curves were obtained using a left
femoral artery approach (7F pigtail) and left femoral venous
approach (8F Goodale Lubin). Cardiac output was calcu-
lated by the Fick method. Oxygen consumption was mea-
sured directly with a metabolic rate meter (Waters Instru-
ments). Left atrial transseptal catheterization was performed
by a right femoral venous approach with a standard Brock-
enbrough needle, using an 8F Mullins transseptal long sheath
and dilator (USC!). After left atrial access was achieved,
4,000 U of heparin was given intravenously.
Mitral valve area was calculated with the Gorlinformula.
Mean transmitral pressure gradient was measured by
planimetry from the simultaneous left atrial and left ventric-
Table 2. Baseline Echocardiographic (Echo) Characteristics of the
34 High Risk and 92 Low Risk Study Patients
High Risk Low Risk p
(n = 34) (n = 92) Value
Left atrial diameter 54 ± 10 51 ± 8 NS
(mm)
Mitral leaflet thickness 2.3 ± 0.5 2.0 ± 0.4 0.04
(I to 4)
Mitral leaflet 2.6 ± 0.7 1.9 ± 0.7 0.02
calcification (I to 4)
Mitral leaflet mobility 2.5 ± 0.6 2.2 ± 0.5 0.03
(I to 4)
Subvalvular disease 2.2 ± 0.7 2.0 ± 0.7 NS
(I to 4)
Echo score (maximum 9.4 ± 1.8 8.2 ± 1.5 0.005
= 16)
Echo score >8 (%) 77 36 0.002
ular pressure recordings, averaging three consecutive beats
if the patient had sinus rhythm and five if atrial fibrillation
was present.
Left ventriculography in the 30° right anterior oblique
projection was performed and mitral regurgitation was quan-
tified according to the criteria of Sellers et al. (19). After
prevalvuloplasty measurements, the dilator was removed
and a 7F balloon tip end-hole catheter was advanced from
the sheath to the left ventricle. The long sheath was then
advanced to the left ventricle and a Teflon-coated exchange
guide wire (diameter 0.038 in. [0.0965 em], length 260 em)
was positioned at the apex of the left ventricle. The 7F
balloon catheter and the sheath were removed and a 7F
6 mm angioplasty catheter balloon (Cook) was passed over
the guide wire to the level of the interatrial septum, and the
septum was dilated. After removal of the balloon catheter,
two 12F balloons in a single shaft catheter (Bifoil, Schneider,
Zurich) or two separate 9F balloons were positioned across
the mitral valve. When a second catheter balloon was used,
a second long exchange guide wire was placed in the left
ventricular apex with use of the long sheath catheter. Two to
five inflations were performed by hand until the waist in the
profile of the balloons caused by mitral stenosis disappeared.
Two separated balloons were used in 54% of patients, one
bifoil catheter balloon in 43% and one single balloon in 3%.
The most frequent balloon diameter combination was 19 +
19 mm. Immediately after mitral valvuloplasty, the balloon
catheters were removed and hemodynamic measurements,
left ventriculography, oximetry and dye-dilution curves
were repeated.
Complete success was defined as a final mitral valve area
:::: 1.5 cm2 and an increase in mitral valve area ::::25%. An
incomplete success was defined as a mitral valve area
:::: 1 cm2 but < 1.5 cm2 with an increase in mitral valve area
::::25%. Hemodynamic failure was defined as a final mitral
valve area < 1cm2 or an increase in mitral valve area <25%.
Follow-up cardiac catheterization. A prospective 6 month
hemodynamic restudy was systematically performed in our
50 patients first treated by mitral valvuloplasty. From this
cohort, 11 patients were in the high risk group. The study
combined right and left heart and transseptal catheterization.
Hemodynamic measurements, left ventriculography, oxim-
etry and dye-dilution curves were performed as before.
Statistical analyses. Mean values and standard deviations
were determined for all variables. Variables measured be-
fore, immediately after valvuloplasty and at repeat catheter-
ization 6 months later were compared by analysis of vari-
ance. Outcome in subgroups was compared by the unpaired
Student's t test. Frequency of events was compared by the
chi-square test, applying the Yates correction when appro-
priate. Multiple logistic regression analysis and stepwise
logistic regression were performed in the standard manner.
Data are presented as mean values ± 1 SD. Probability (p)
values <0.05 were considered significant.
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Table 3. Hemodynamic Results Before and After Completed
Percutaneous Mitral Valvuloplasty in 28 High Risk Patients
% Inc. MVA
150
Figure 1. Percent increase in mitral valve area (% Inc. MVA) after
completed valvuloplasty as a function of echocardiographic (Echo)
score in 28 high risk patients.
Pre-PMV Post-PMV p Value
2.8 ± 0.9 3.4 ± 1.0 0.0008
15.6 ± 5.8 6.4 ± 2.6 0.0001 100
8.7 ± 4.7 7.6 ± 3.5 0.005
26.2 ± 6.6 15.4 ± 4.9 0.0001
44.6 ± 17.2 33.3 ± 12.5 0.0001
597 ± 513 388 ± 294 0.005
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Figure 2. Percutaneous mitral valvuloplasty in 34 high risk patients.
Overall results are plotted as afunction of echocardiographic (Echo)
score.
14% and hemodynamic failure in 5% (p = 0.(04). Among 32
clinical, echocardiographic, hemodynamic and procedural
variables analyzed by univariate analysis, we found that
hemodynamic success in high risk patients (versus failure or
incomplete success) correlated with a higher cardiac output
(3.3 + 0.7 versus 2.6 + l.lliters/min; p < 0.09), lower right
atrial pressure (7.6 ± 3.8 versus 10.8 ± 8 mm Hg; p < 0.04)
and lower echocardiographic score (8.4 ± 1.6 versus 10.6 ±
1.3; p < 0.0007). By stepwise logistic regression, echocar-
diographic score (p < 0.001) was the only independent
predictive factor of success. By univariate analysis, the
same variables were associated with hemodynamic failure
(versus success or incomplete success). Stepwise logistic
regression identified leaflet thickness (p < 0.001) and echo-
cardiographic score (p < 0.08) to be independent predictors
of procedural failure.
The percent increase in mitral valve area after percuta-
neous mitral valvuloplasty correlated with the echocardio-
graphic score (Fig. i). The overall outcome of the procedure
was also strongly dependent on echocardiographic score
(Fig. 2). With an increase in this score, the probability of
hemodynamic success decreased, whereas the likelihood of
Results
Technical failures and complications. Percutaneous mitral
valvuloplasty was not completed because of a procedural
failure or major complication, or both, in 6 (18%) of the 34
surgical high risk patients (versus 5% of the 92 low risk
patients; p = 0.04). Three technical failures occurred; in two
patients, the mitral valve could not be crossed with the
balloon. One of these patients died 48 h later because of
multisystem failure; he was 79 years old, in functional class
IV and had an old myocardial infarction and an enlarged left
atrium (70 mm). The other patient died during elective mitral
valve replacement after the failed procedure. In the remain-
ing patients, the mitral valve could be crossed, but the
balloon could not be positioned properly across the valve.
Major complications occurred in three patients: left ven-
tricular perforation in a 73 year old patient who died 24 h
after urgent surgery, left atrial perforation with acute tam-
ponade in a patient who underwent urgent surgery without
further complication and left ventricular perforation with
formation of an apical pseudoaneurysm in the remaining
patient.
By multivariate analysis, no significant difference was
found between these 6 patients with incomplete valvulo-
plasty and the 28 in whom valvuloplasty was completed.
Nevertheless, 5 of the 6 patients had mitral calcifications on
fluoroscopy (versus 22 of 28 with complete valvuloplasty),
mean echocardiographic score higher (II ± 2 versus 9 ± 2),
left atrial diameter larger (60 ± 7 versus 53 ± 10 mm) and the
patients older (69 ± 12 versus 64 ± II years).
Immediate hemodynamic results after completed valvulo-
plasty (Table 3). A complete success was obtained in 18
(65%) of the remaining 28 patients, an incomplete success in
4 (14%) and hemodynamic failure in 6 (21%). In comparison,
in the 92 low risk patients, complete hemodynamic success
was obtained in 81% (p = 0.0001), incomplete success in
Pre-, Post-PMV = before and after percutaneous mitral valvuloplasty,
respectively.










Table 4. Immediate and 6 Month Hemodynamic Follow-Up Data




Figure 3. Cumulative Kaplan-Meier survival curve in 34 high and 92
low surgical risk patients (pts).
the 14 patients followed up for ~12 months, functional class
worsened by one grade in 1patient and was unchanged in 13.
In comparison, the overall outcome of the 92 low risk
patients included elective or urgent surgery in 6 (7%) and
death in 2 (2%), including one perioperative death. At 6
months, 82% had improvement by at least one functional
class. Among 44 patients followed up for ~12 months, 39
had no further change in functional class and functional class
worsened by one grade in 5.
Follow-up catheterization data (Table 4). At 6 ± 1
months. 11 unselected patients in the surgical high risk group
prospectively underwent repeat catheterization (7 with com-
plete valvuloplasty success, 1with incomplete success and 3
with valvuloplasty failures). Cardiac output, mitral valve
area and pulmonary arteriolar resistance remained un-
changed 6 months after percutaneous mitral valvuloplasty.
Restenosis, defined as a loss of ~50% of the gain achieved in
mitral valve area and a mitral valve area <1.5 cm2 , was
found in one of the seven patients who had complete
hemodynamic success. Echocardiographic measurement of
the mitral valve area by pressure half-time was also available
before. immediately after and 6 months after valvuloplasty in
five other unselected patients. The mean area increased from
0.8 ± 0.2 to 1.5 ± 0.3 cm2 (p < 0.01) immediately after the
procedure and remained unchanged (1.4 ± 0.2 cm2) at the 6
month follow-up study.
Mitral regurgitation, graded on a scale of0 to 4, increased
after mitral valvuloplasty from a mean of 0.7 ± 0.6 to 1.2 ±
0.7 (p = 0.001) and remained unchanged (1.0 ± 1.0; p = NS)
at the 6 month follow-up study. Mitral regurgitation re-
mained unchanged after valvuloplasty in 15 (56%) of 27
patients and increased by one grade in the remaining 12
patients. Only one patient had grade 3/4 mitral regurgitation
after valvuloplasty.
p = NS for all values. Abbreviations as in Table 3.
Immediate 6 Months
(n = II) (n = II)
Cardiac output (liters/min) 3.4 ± I.1 3.5 ± 1.2
Pressure (mm Hg)
Mitral valve gradient 5.1 ± I.1 6.8 ± 3.9
Right atrial 7.3 ± 3.4 6.2 ± 3.3
Left atrial 13.5 ± 3.4 16.5 ± 6.9
Mean pulmonary artery 33.5 ± 12.4 30.7 ± 10.7
Pulmonary arteriolar resistance 457 ± 326 378 ± 283
(dynes's- "cm-
5)






Mitral valve area (cm2) 1.7 ± 0.5 1.7 ± 0.8
24 Months
3 High risk pts






















NYHA class I V
Figure 4. New York Heart Association (NYHA) functional class
before percutaneous mitral valvuloplasty (PMVj at 6 and 12 month
clinical follow-up study in 25 patients.
Pre-PMV 6 months 12 months
n =25 n =25 n =14
failure, major complications or incomplete success in-
creased.
Death due to cerebral embolism occurred in one patient
48 h after completed but unsuccessful valvuloplasty. This
patient had been classified in the surgical high risk group
because of severe pulmonary hypertension (pulmonary arte-
riolar resistance 1,422 dynes·s- 1·cm-5).
Six month clinical follow-up. The cumulative survival
curve of the 34 high risk patients compared with that of the
92 low risk patients is illustrated in Figure 3. Their overall
outcome at a mean follow-up period of 9.3 ± 4.2 months in
terms of intention to treat by mitral valvuloplasty included
urgent or elective surgery in eight (24%) and death in six
(18%), including two perioperative deaths. Among the six
patients with hemodynamic failure, two underwent elective
valve replacement with no mortality, one had repeat valvu-
loplasty that was successful and one who was not operated
on died at 6 months (cause unknown). One of the four
patients with incomplete hemodynamic success died from
pneumonia 1 month after mitral valvuloplasty. Only 1of the
18 patients with a successful procedure needed repeat val-
vuloplasty because of restenosis. At 6 months, 20 (80%) of
the 25 patients alive who had not crossed over to surgery had
improvement by at least one functional class (Fig. 4). Among
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Atrial shunting was detected by venovenous dye-dill/tion
curves immediately after mitral valvuloplasty in 71% of high
risk patients (76% in low risk patients; p = NS). Mean atrial
shunting assessed by the ratio of pulmonary to systemic flow
(Qp/Qs) was 1.2 ± OJ and only four patients (14%) had a
Qp/Qs ratio> 1.5 (versus II %of low risk patients; p = NS).
At the 6 month hemodynamic follow-up study, left to right
atrial shunting was detected in only 27% of patients and
Qp/Qs ratio was always <1.5.
Discussion
This study focuses on a group of patients who were at
increased risk for either surgical commissurotomy or mitral
valve replacement. Our surgical team evaluated the opera-
tive risk at > 15% in all cases and refused to operate on 16 of
the 34 patients. Most of the patients would have required
mitral valve replacement because of long-standing rheumatic
mitral valve disease, with calcifications seen either on fluo-
roscopy or echocardiography.
Mitral valve surgery versus percutaneous valvuloplasty.
Because a control group was not included in this study, the
next best option is to compare the results and complications
of valvuloplasty with the expected outcome after mitral
valve replacement. Such comparisons should be accepted
with a degree of caution because patients in different series
may not be similar.
The overall immediate surgical mortality rate associated
with valve replacement for mitral stenosis ranges from 3.2%
to 11% (13,14,20,21). It is higher (13.5% to 16.2%) in patients
>70 years of age (14,22). Mortality is also related to func-
tional class (15), presence of coronary artery disease (20),
need for other valve surgery (15) or simultaneous coronary
bypass surgery, repeat sternotomy and ejection fraction (14).
The mortality rate in patients in functional class IV ranges
from 12.4% to 26% (14-16,21). Simultaneous coronary by-
pass surgery is associated with a risk of 10% to 22%
(14,20,21). The need for tricuspid annuloplasty increases the
risk of mitral valve replacement to 18% (I5), repeat sternot-
omy to 12.6% (14) and an ejection fraction between 0.20 and
0.40 to 9.7% (I4). Since the introduction of cold cardiople-
gia, the mortality rate for mitral valve replacement in pa-
tients with mitral stenosis and pulmonary hypertension has
decreased significantly to 7.7% and 5.6% in two recent
studies (23,24).
In comparison, the immediate mortality rate in this series
of patients undergoing mitral valvuloplasty was 9% (3 of 34
patients). The procedure was completed in 28 (82%) of the 34
surgical high risk patients; technical failure occurred in 3
patients and major complications (namely, left atrial or
ventricular perforation) in 3. This 82% rate of completed
mitral valvuloplasty is low compared with that in our low
risk patients (95%; p = 0.04). The difference is probably
related to a larger left atrial diameter and more abnormal
mitral valve morphology (Table 2), which cause technical
problems in positioning the balloon properly across the
mitral valve. The success rate for mitral valvuloplasty in-
creases with experience; however, this factor did not ac-
count for the difference between high and low risk groups or
completed and in completed mitral valvuloplasty procedures
in this series.
In vivo (25) and postmortem in vitro (12,26,27) studies
have shown that successful percutaneous mitral valvulo-
plasty may result from both separation of fused commissures
and fracture of nodular calcium. Thus, the presence of
extensive calcific deposits, classically held to be a contrain-
dication to mitral valvuloplasty, did not preclude a favorable
result (II). Percutaneous mitral valvuloplasty has been
shown to be an effective nonsurgical procedure in selected
patients with mitral calcifications (6,10), and other studies
(28) have shown that it could be effectively applied in some
patients who are unsuitable for surgery.
Hemodynamic results. The immediate hemodynamic re-
sults of the procedure (Table 3) included an increase in mitral
valve area from 0.9 ± 0.4 to 1.6 ± 0.6 cm2 (p < 0.0008) and
a simultaneous decrease in left atrial pressure, mean pulmo-
nary artery pressure, mitral valve gradient and total pulmo-
nary resistance. The rate of complete plus incomplete suc-
cess was relatively low compared with that in low risk
patients (79% versus 95%, p < 0.04). One other series (28)
has shown that the hemodynamic results in older patients
were worse than in younger patients with a pliable noncal-
cified valve.
Like Wilkins et al. (I8) and Palacios et al. (29), we found
that the hemodynamic results correlated with the echocar-
diographic score (Fig. I). With higher echocardiographic
scores, the success rate decreases and the risk of complica-
tions increases (Fig. 2). Using a different classification of
mitral valve morphology, other studies (7,30,31) reported the
same negative correlations between postvalvuloplasty mitral
valve area and the prevalvuloplasty severity of anatomic
abnormalities of the mitral valve and subvalvular apparatus.
The majority of our surgical high risk patients had an
echocardiographic score >8 and their mitral valve area
before valvuloplasty was smaller than that in low risk
patients (0.9 ± 0.4 versus 1.1 ± 0.3 cm2; p = 0.0007). Thus,
the worse hemodynamic results obtained in high risk pa-
tients relate to their unfavorable baseline valve characteris-
tics.
Complications. Mitral regurgitation increased by one
grade after percutaneous mitral valvuloplasty in nearly 50%
of the patients, but no patient had an increase of more than
one grade. Mitral regurgitation may also develop or worsen
after surgical mitral commissurotomy (9). Approximately
20% to 50% of the patients undergoing mitral valvuloplasty
have a small increase in mitral regurgitation as reported
previously (6,7,29-32). No severe mitral regurgitation was
induced in our high risk patients despite severe abnormali-
ties of mitral valve morphology.
Left to right atrial shunting was a common finding after
mitral valvuloplasty (71%), higher than the 10% to 25% rate
previously reported (5,7,29,31). This difference is a conse-





quence of the venovenous dye-dilution technique used for
shunt detection in our study. Only 4 of the 28 patients with
a completed procedure had a Qp/Qs ratio >1.5, and in no
case was there any clinical consequence. Left to right atrial
shunting decreased or disappeared in most patients at the 6
month follow-up study.
Clinical follow-up. After completed percutaneous mitral
valvuloplasty, approximately 80% of the patients were clin-
ically improved and in functional class I or II at 6 months.
One patient died at 1 month and another, who had severe
obstructive pulmonary disease whose procedure classified as
a hemodynamic failure, had no improvement and remained
in functional class IV. The four patients with hemodynamic
failure who were not operated on were clinically improved;
although their percent increase in mitral valve area was
>25%, their procedure could not be classified as an incom-
plete success because their mitral valve area remained
<I cm2• Only one patient, classified as having an incomplete
hemodynamic success, became clinically worse between 6
months and I year. These results are concordant with
previous studies of percutaneous mitral valvuloplasty in
patients >65 years of age or with "inoperable" mitral
stenosis (28), in which, respectively, 52% and 83% of pa-
tients had significant improvement in symptoms at follow-up
study.
The overall outcome of high risk patients can be com-
pared with the natural history of severe mitral stenosis with
medical treatment (33). The 1year mortality rate in patients
in functional class IV (11 of 34 patients in our study were in
class IV) is 57% and that of patients in class II or III with
atrial fibrillation is 13%.
Hemodynamic follow-up. In 11 unselected patients under-
going repeat catheterization at 6 months, hemodynamic
variables were not changed significantly compared with
values immediately after valvuloplasty. The clinical and
echocardiographic features of these 11 patients did not differ
from those of the remainder of the high risk group. Resteno-
sis was found in only one of the seven patients with complete
success who underwent repeat catheterization. Palacios et
al. (29) found a 70% restenosis rate in patients with an
echocardiographic score >8, but the definition of restenosis
(that is, loss of 2:50% of the gain achieved in mitral valve
area) was less restrictive than our definition. By multiple
stepwise regression analysis, echocardiographic score was
the single most important factor predictive of restenosis. In
contrast, the rate of complete success was low in patients
with a high echocardiographic score in our study, and they
could not develop restenosis because it was arbitrarily
defined as a loss of 2:50% of the gain achieved in mitral valve
area and a mitral valve area <1.5 cm2 in patients with
complete success.
Conclusions. In patients who are at high risk for surgery,
the risk of percutaneous ,mitral valvuloplasty seems to be
acceptable compared with that of valve replacement, the
operation required in most cases. Although these patients
have more severe mitral stenosis and less hemodynamic
improvement after valvuloplasty, a complete hemodynamic
success is obtained in 62% and short-term functional im-
provement occurs in 80% of those with a completed valvu-
loplasty procedure. However, in high risk patients with
major abnormalities of valve morphology, as evidenced by
an echocardiographic score 2: II, valvuloplasty should be
considered only if mitral valve replacement is not an option,
because the hemodynamic success rale is low and compli-
cations are frequent.
Follow-up studies are needed to assess the long-term
efficacy of this procedure in high risk patients. Short- and
long-term results in low risk patients, who usually have a low
echocardiographic score, should be comparable at least with
the results of closed commissurotomy, but in high risk
patients, a randomized comparison of percutaneous mitral
valvuloplasty and surgery should be performed.
We thank Monique Brouillette. RN and Maryse Caron, RN for their excellent
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